Markets concluded the week with a notable shift in sentiment. After reaching record highs earlier, U.S. stocks closed lower on Friday, impacted by macroeconomic concerns.

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Fintel reports that on July 7, 2025, Leerink Partners initiated coverage of Rhythm Pharmaceuticals (NasdaqGM:RYTM) with a ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

We just received data on a new analyst forecast for $RYTM. Joseph Stringer from Needham set a price target of 95.0 for RYTM.

Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study evaluating the investigational oral melanocortin-4 receptor (MC4R ...

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than ...

Get today's Rhythm Pharma stock news. We cover the latest Rhythm Pharma headlines and breaking news impacting Rhythm Pharma stock performance.

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% higher in ...